Nav: Home

Synodos for NF2 Consortium publishes key results of its work

June 14, 2018

The Synodos for NF2 consortium of the Children's Tumor Foundation (CTF) today published its first set of results and released its second set of data in the leading scientific journal PLOS ONE. Synodos is the Foundation's innovative team science collaborative that brings researchers, clinicians and patients together in a shared data environment, in order to develop treatments for NF patients at an accelerated pace. Established in 2014, the $3 million project is a combined effort among 12 leading research labs at 8 institutions.

The Synodos for NF2 team released its first set of results and data in the scientific journal PLOS ONE, entitled Traditional and Systems Biology Based Drug Discovery for the Rare Tumor Syndrome Neurofibromatosis Type 2. In line with the Foundation's principles of open-access and data sharing, the journal is making the full article available to all, with immediate access to the data.

The primary aim of the Synodos for NF2 team was to find treatments that could be used for both meningioma and schwannoma by using a drug discovery approach of selecting mechanistically relevant compounds. The team integrated innovative research approaches such as Next Generation Sequencing (NGS) and Kinome profiling. These two techniques allow analysis of the alteration in expression of genes and proteins in cells or animal models.

A core finding was that while schwannomas and meningiomas are both initiated by merlin loss, the distinctly different responses to that loss of function are likely to prescribe that a single drug (target) is unlikely to be optimally effective in both cell types. Instead, it is likely that different drugs or combos (a cocktail of two or more drugs) aimed at distinct targets will be required to treat these two tumor types. In fact, the first three single drugs tested (Panobinostat, CUDC-907 and GSK2126458) were only mildly active in preventing tumors from growing. The next set of experiments started looking at drug combinations and the team reported that the drug Dasatininb, a multi-kinase inhibitor in combination with AZD-2014 or INK128, both dual mTORC1/2 inhibitors, suppressed tumor growth up to ~85% in a meningioma animal model (this last result was reported earlier in March 2018 by the Synodos team in the scientific journal Neuro-Oncology. That publication can be found here:

Additionally, the work of the Synodos for NF2 consortium has filled a critical gap in the understanding of how the NF2 mutation and the absence of merlin influence tumor cell behavior in both meningiomas and schwannomas. The collective effort of twelve research groups succeeded in:
    (1) creating a new pipeline of well-validated tools for NF2-associated drug discovery with fully characterized isogenic pairs of meningioma and schwannoma cell systems;

    (2) gaining conceptual insights into disease mechanisms via transcriptome and kinome interrogation that indicate that different drugs are likely to be needed to treat meningioma and schwannoma;

    (3) validating pathways and targets that are altered based on tumor type and in response to targeted pathway inhibition in the setting of NF2; and

    (4) building an openly accessible database for community sharing and mining of drug treatment, transcriptome and kinome data from isogenic schwannoma and meningioma cell systems. This data presents several targets to consider for single agent and combination therapy in the short term, and provides a deep and rich open access data resource for the broader research community seeking treatments for NF2-associated meningioma and schwannoma for the long term.

The Synodos team is actively working on finalizing the latest findings, which will also be published as a follow up to this research release.

Ultimately, these newly released results and data are providing, for the first time, a critical resource that will be invaluable to the NF2 research community. This work illustrates that the CTF model of bringing together scientists of diverse expertise areas improves the ability to discover new therapeutic strategies to treat these highly devastating tumors.

The full article in PLOS ONE can be found here:

The Children's Tumor Foundation is a 501(c)(3) not-for-profit organization dedicated to funding and driving innovative research that will result in effective treatments for the millions of people worldwide living with neurofibromatosis (NF), a term for three distinct disorders: NF1, NF2, and schwannomatosis. NF causes tumors to grow on nerves throughout the body and may lead to blindness, deafness, bone abnormalities, disfigurement, learning disabilities, disabling pain, and cancer. NF affects 1 in every 3,000 births across all populations equally. There is no cure yet - but the Children's Tumor Foundation mission of driving research, expanding knowledge, and advancing care for the NF community fosters our vision of one day ending NF. For more information, please visit


Simon Vukelj
Vice President, Marketing and Communications
Children's Tumor Foundation
(212) 344-7568

Children's Tumor Foundation

Related Drug Discovery Articles:

Choosing a simpler path to drug discovery
Researchers from Kyoto University, MIT, and ETH Zurich have developed a compact drug discovery method using simple models and small data sets.
Drug discovery researchers awarded grant to refine malaria drug
A research team from the Virginia Tech Center for Drug Discovery has received a $431,126 two-year grant from the National Institutes of Health to make improved versions of a promising compound called MMV008138, or 8138 for short.
New computational tool may speed drug discovery
A new computational tool called fABMACS is helping scientists see beyond static images of proteins to more efficiently understand how these molecules function, which could ultimately speed up the drug discovery process.
Paving the road to drug discovery
When treated with an anti-cancer drug, ICRF-193, fission yeast produce an 'arched and snapped' phenotype that may be used to screen for other cancer drugs.
Open-source drug discovery a success
In what is being called the first-ever test of open-source drug-discovery, researchers from around the world have successfully identified compounds to pursue in treating and preventing parasite-borne illnesses such as malaria as well as cancer.
Celgene joins DNDi's 'Drug Discovery Booster'
The biopharmaceutical company Celgene has become the fifth company to join the 'Neglected Tropical Diseases Drug Discovery Booster' consortium, a new initiative to accelerate and cut the cost of early stage drug discovery for two of the world's most neglected diseases, leishmaniasis and Chagas disease.
Speeding up drug discovery to fight tuberculosis
Researchers at the Institute for Systems Biology and Center for Infectious Disease Research in Seattle have deciphered how the human pathogen Mycobacterium tuberculosis is able to tolerate the recently approved FDA drug bedaquiline.
Deep learning applied to drug discovery and repurposing
Scientists from Insilico Medicine in collaboration with Datalytic Solutions and Mind Research Network trained deep neural networks to predict the therapeutic use of large number of multiple drugs using gene expression data obtained from high-throughput experiments on human cell lines.
Breast cancer drug discovery offers hope of new treatments
A new drug discovery approach has yielded a potential therapy for breast cancer that may be more effective than existing medicines.
Current cancer drug discovery method flawed: Study
The primary method used to test compounds for anti-cancer activity in cells is flawed, Vanderbilt University researchers report May 2 in Nature Methods.

Related Drug Discovery Reading:

Drugs: From Discovery to Approval
by Rick Ng (Author)

Drug Discovery: A History
by Walter Sneader (Author)

Basic Principles of Drug Discovery and Development
by Benjamin Blass (Author)

Drug Discovery and Development: Technology in Transition
by Raymond G Hill (Editor)

Drug Discovery: Practices, Processes, and Perspectives
by Jie Jack Li (Editor), E. J. Corey (Editor)

Peptide-based Drug Discovery: Challenges and New Therapeutics
by Ved Srivastava (Editor)

Bioinformatics and Computational Biology in Drug Discovery and Development
by William T. Loging (Editor)

Drugs: From Discovery to Approval
by Rick Ng (Author)

Successful Drug Discovery
by János Fischer (Editor), Wayne E. Childers (Editor)

Drug Discovery: From Bedside to Wall Street
by Tamas Bartfai (Author), Graham V. Lees (Author)

Best Science Podcasts 2018

We have hand picked the best science podcasts for 2018. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Hacking The Law
We have a vision of justice as blind, impartial, and fair — but in reality, the law often fails those who need it most. This hour, TED speakers explore radical ways to change the legal system. Guests include lawyer and social justice advocate Robin Steinberg, animal rights lawyer Steven Wise, political activist Brett Hennig, and lawyer and social entrepreneur Vivek Maru.
Now Playing: Science for the People

#495 Earth Science in Space
Some worlds are made of sand. Some are made of water. Some are even made of salt. In science fiction and fantasy, planet can be made of whatever you want. But what does that mean for how the planets themselves work? When in doubt, throw an asteroid at it. This is a live show recorded at the 2018 Dragon Con in Atlanta Georgia. Featuring Travor Valle, Mika McKinnon, David Moscato, Scott Harris, and moderated by our own Bethany Brookshire. Note: The sound isn't as good as we'd hoped but we love the guests and the conversation and we wanted to...